Drugs / HGP1910
last change Feb 2021 re-read 3 minutes ago

HGP1910

Developed for
hyperlipoproteinemia
Investigated by
Hanmi Pharmaceutical Company Limited

Trials 2

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04762407 Nov 2020 → Feb 2021 — Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT04652349 Jul → Dec 2020 hyperlipoproteinemia Hanmi Pharmaceutical Company Limited Completed Met primary

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HGP1910 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652349 ↗
1

NCT04762407 ↗